Abstract:
OBJECTIVE To investigate the effect of ivabradine on platelet activity in rats with coronary heart disease based on PI3K/Akt signaling pathway.
METHODS After different treatments, male Wistar rats were divided into control group, model group, ivabradine hydrochlorid group(10 mg·kg−1) and aspirin group(10 mg·kg−1), 6 rats in each group were gavaged once a day for 4 weeks. Echocardiography techniques were used to evaluate the left ventricular ejection fraction(LVEF) and left ventricular fractional shortening(LVFS). The plasma platelet aggregation rate was measured, and the expression levels of platelet surface proteins CD62p and PAC-1 were detected by flow cytometry; plasma levels of plasma beta platelet globulin(β-TG), platelet factor 4(PF 4), interleukin 6(IL-6), interleukin 1β(IL-1β), tumor necrosis factor α(TNF-α) were measured by enzyme-linked immunosorbent assay; using a biochemical test kit to detect the levels of total cholesterol(TC), triglyceride(TG), low-density lipoprotein cholesterol(LDL-C), and high-density lipoprotein cholesterol(HDL-C) in rat serum. The levels of serum creatine kinase(CK), creatine kinase MB isoenzyme(CK-MB), lactate dehydrogenase(LDH), and cardiac troponin T(cTnT) were measured using colorimetric method; Western blotting was used to detect changes in PI3K/Akt pathway proteins in platelets; Using hematoxylin eosin staining and Masson staining to observe the pathological changes and fibrosis of myocardial tissue in each group.
RESULTS After 4 weeks of treatment, compared with the rats in the model group, LVEF and LVFS were increased, platelet aggregation rate was decreased, the expression of the platelet surface proteins CD62p, PAC-1 were decreased, serum levels of β-TG, PF, IL-6, IL-1β and TNF-α were decreased; serum levels of TC, TG, LDL-C were decreased, and serum levels of HDL-C was increased; serum levels of CK, CK-MB, LDH, and cTnT were decreased in the ivarabradine group. And ivabradine activated the phosphorylation of PI3K/Akt pathway proteins in platelet cells; it reduced myocardial tissue fibrosis and improved myocardial histopathological changes.
CONCLUSION Ivarbredin can inhibit platelet aggregation in the plasma of rats with coronary heart disease, suppress the expression of platelet surface proteins CD62p and PAC-1, as well as the secretion of β-TG and PF4, and reduce the levels of inflammatory factors and blood lipid, alleviate myocardial fibrosis and improve pathological changes in myocardial tissue, improve heart function. The mechanism may be related to the phosphorylation of PI3K/Akt pathway proteins in activated platelet cells.